Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: A retrospective primary care-based analysis

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Sharplin, Peter ^a   Gordon, Jason ^a   Peters, John R ^b   Tetlow, Anthony P ^a   Longman, Andrea J ^a   McEwan, Philip ^a  

^a CHKS Health Economics Unit   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT CHANGE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; EVALUATION; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICS;

ADULT; BODY WEIGHT; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 61649113766     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-9     Document Type: Article

References (37)

1. National Institute for Health and Clinical Excellence The management of type 2 diabetes (update) (Clinical guideline 66.) London: NICE 2008 http://www.nice.org.uk/Guidance/CG66
2. National Institute for Health and Clinical Excellence Diagnosis and management of type 1 diabetes in children, young people and adults Clinical guideline 15 London: NICE 2004 http://www.nice.org.uk/guidance/ index.jsp?action=byID&o=10944
3. IDF Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care Diabet Med 2006, 23:579-593 10.1111/j.1464-5491.2006.01918.x 16759299
4. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus Endocr Pract 2007, 13(Suppl 1):1-68 17613449
5. American Diabetes Association Standards of medical care in diabetes-2008 Diabetes Care 2008, 31(Suppl 1):S12-54 10.2337/dc08-S012 18165335
6. Department of Health Diabetes National Service Framework Guidelines http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Diabetes/ index.htm
7. Nathan DM Buse JB Davidson MB Ferrannini E Holman RR Sherwin R Zinman B Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2008, 31:1-11 10.2337/dc08-0545
8. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus NEJM 1993, 329:977-986 10.1056/NEJM199309303291401 8366922
9. UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group. (UKPDS 34) Lancet 1998, 352:854-865 10.1016/S0140-6736(98)07037-8 9742977
10. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998, 352:837-853 10.1016/S0140-6736(98)07019-6 9742976
11. Roach P Trautmann M Arora V Sun B Anderson JH Jr Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group Clin Ther 1999, 21:523-534 10.1016/S0149-2918(00)88307-1 10321421
12. Heinemann L Linkeschova R Rave K Hompesch B Sedlak M Heise Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 2000, 23:644-649 10.2337/diacare.23.5.644 10834424
13. Janka HU Plewe G Riddle MC Kliebe-Frisch C Schweitzer MA Yki-Jarvinen H Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 2005, 28:254-259 10.2337/diacare.28.2.254 15677775
14. Hammer H Klinge A Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice Int J Clin Pract 2007, 61:2009-2018 2228388 17997807 10.1111/ j.1742-1241.2007.01598.x
15. Schiel R Muller UA Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: The Switch pilot study Exp Clin Endocrinol Diabetes 2007, 115:627-633 10.1055/ s-2007-984445 18058596
16. Davies M Sinnassamy P Storms F Gomis R Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies Diabetes Res Clin Pract 2008, 79:368-375 10.1016/j.diabres.2007.09.013 17980928
17. Bourke A Dattani H Robinson M Feasibility study and methodology to create a quality-evaluated database of primary care data Inform Prim Care 2004, 12:171-177 15606990
18. Currie CJ Poole CD Tetlow T Holmes P McEwan P The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis Curr Med Res Opin, Suppl 2007, 23:S33-S39 10.1185/030079907X167534
19. Poole CD Tetlow T McEwan P Holmes P Currie CJ The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis Curr Med Res Opin, Suppl 2007, 23:S41-S48 10.1185/030079907X167589
20. Brown PJ Warmington V Laurence M Prevost AT Randomised crossover trial comparing the performance of Clinical Terms Version 3 and Read Codes 5 byte set coding schemes in general practice BMJ 2003, 326:1127 156010 12763986 10.1136/bmj.326.7399.1127
21. Rosenstock J Ahmann AJ Colon G Scism-Bacon J Jiang H Martin S Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/ lispro) versus basal/bolus (glargine/lispro) therapy Diabetes Care 2008, 31:20-25 10.2337/dc07-1122 17934150
22. Schreiber SA Haak T Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: An observational study of everyday practice in 12,216 patients Diabetes Obes Metab 2007, 9:31-38 10.1111/j.1463-1326.2006.00593.x 17199716
23. Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Hadden D Turner RC Holman RR Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 2000, 321:405-412 27454 10938048 10.1136/ bmj.321.7258.405
24. Benson K Hartz AJ A comparison of observational studies and randomized, controlled trials NEJM 2000, 342:1878-1886 10.1056/NEJM200006223422506 10861324
25. Concato J Shah N Horwitz RI Randomized, controlled trials, observational studies, and the hierarchy of research designs NEJM 2000, 342:1887-1892 1557642 10861325 10.1056/NEJM200006223422507
26. Cramer JA Pugh MJ The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin? Diabetes Care 2005, 28:78-83 10.2337/diacare.28.1.78 15616237
27. Lee WC Balu S Cobden D Joshi AV Pashos CL Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data Clin Ther 2006, 28:1712-1725 10.1016/ j.clinthera.2006.10.004 17157128
28. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal London: NICE 2008 http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
29. Benedetti M Humburg E Dressler A Ziemen M A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes Horm Metab Res 2003, 35:189-196 10.1055/s-2003-39080 12734781
30. Gallen I Carter C Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes Pract Diab Int 2004, 21:110-114 10.1002/pdi.604
31. Erickson TN Devine EB O'Young TS Hanson LJ French B Brennan C Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine Am J Health Syst Pharm 2006, 63:1862-1871 10.2146/ajhp050439 16990633
32. Albright ES Desmond R Bell DS Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy Diabetes Care 2004, 27:632-633 10.2337/diacare.27.2.632 14747268
33. Hamann A Matthaei S Rosak C Silvestre L A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes Diabetes Care 2003, 26:1738-1744 10.2337/diacare.26.6.1738 12766103
34. Fritsche A Schweitzer MA Haring HU Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial Ann Intern Med 2003, 138:952-959 12809451
35. Raccah D Bretzel RG Owens D Riddle M When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev 2007, 23:257-264 10.1002/dmrr.733 17315242
36. Schreiber SA Russmann A The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice Curr Med Res Opin 2006, 22:335-341 10.1185/ 030079906X80468 16466605
37. Schreiber SA Russmann A Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice Curr Med Res Opin 2007, 23:3131-3136 10.1185/030079907X242827 17988433